Regulatory Affairs Outsourcing Allows Businesses To Free Up Resources And Refocus Their Resources On Strategic Activities
Regulatory Affairs Outsourcing |
Regulatory Affairs Outsourcing (RAO) is an increasingly used practice by companies in the pharmaceutical, biotechnological, and medical device sectors. It is a cost-effective way to meet regulatory requirements and obtain approvals for new products.
Increasing costs and
the need for resources are the main drivers behind the Regulatory
Affairs Outsourcing trend. Moreover, the demand for outsourcing is
increasing in emerging economies. The rapid development of the life sciences sector
is another driving factor.
The Global Regulatory
Affairs Outsourcing Market Size Was Valued At US$ 3,683.7 Million
In 2019, And Is Expected To Exhibit A CAGR Of 12.0% Over
The Forecast Period (2019 – 2027).
Several pharmaceutical
and medical device companies are investing in R&D activities. However, they
are not able to build an in-house regulatory affairs team due to lack of
capital. Hence, they prefer to outsource the services to a service provider
with the necessary experience.
Furthermore, Regulatory Affairs Outsourcing firms
have the ability to expedite the regulatory process. They can also help ensure
regulatory compliance. They can write protocols for clinical trials and provide
digital IND safety reporting services. This allows them to supplement their
current regulatory staff.
Regulatory Affairs Outsourcing is a process where an
organization pays a service provider to perform specific tasks. Some of the
activities that can be outsourced are: eCTD submissions, digital IND safety
reporting, drug labeling and clinical trial applications.
Regulatory Affairs Outsourcing helps refocus the
regulatory team's attention to core competencies, such as regulatory
compliance, product approval, and data management. By outsourcing these
non-core activities, businesses can increase their focus on marketing, sales,
and other core functions. This can also result in more efficient reimbursements
and reduced costs. Depending on the scope of the project, companies can choose
among various outsourcing models.
Regulatory affairs
outsourcing companies can also supplement a company's current regulatory team.
These firms can write protocols for clinical trials and assist in getting a new
product approved. However, establishing an in-house regulatory affairs
department in an offshore facility is not feasible. To overcome this challenge,
businesses must outsource the activities.
Regulatory Affairs
Outsourcing firms are able to reduce excessive workloads. Often, these
workloads are caused by overly ambitious goals. Alternatively, they may be
triggered by external factors.
Eli Lilly acquired
Dermira’s immunology portfolio in 2020. This is estimated to have a positive
impact on the development of COVID-19 vaccines.
Comments
Post a Comment